Disclosed are 6-hydroxy benzopyrazine / quinoxaline derivatives as represented by the general formula (I), wherein R' is NR6R7 or OR8； R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, nitro, cyano, halogen, -C(O)R11, C(O)OR11, OR11, SR11, S(O)R11, S(O)2R11, NR9R10, CONR9R10, N(R9)C(O)R11, N(R9)C(O)OR11, OC(O)NR9R10, N(R9)C(O)N9R10, P(O)(OR11)2, SO2NR9R10, N(R9)SO2R11, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, and heteroaryl； and wherein the remaining substituents are as defined herein. Representative compounds include N-[(6-hydroxy-3-phenyl-5-quinoxalinyl)carbonyl] glycine； N-{ [7-(3,5-difluorophenyl)-6-hydroxy-5-quinoxalinyl]carbonyl} glycine； N-[(3-(3,4-difluorophenyl)-6-hydroxy-7- { 3-[(1-methylethyl)oxy]phenyl} -5-quinoxalinyl)carbonyl]glycine； N-{ [2-(3-fluorophenyl)-6-hydroxy-5-quinoxalinyl]carbonyl} glycine； N-{ [8-(2-furanyl)-6-hydroxy-5-quinoxalinyl]carbonyl} glycine； N-{ [6-hydroxy-8-(1,3-thiazol-5-yl)-5-quinoxalinyl]carbonyl} glycine and N-{ [6-hydroxy-2-(3-pyridinyl)-5-quinoxalinyl]carbonyl} glycine. Further disclosed is a pharmaceutical composition which comprises a compound of formula (I) or a salt, solvate, as defined above and one or more of pharmaceutically acceptable carriers, diluents and excipients for treating anaemia.
